Generic vs brand: what actually differs
On the things regulators test, the two are required to match. The real differences sit in price, appearance and a small number of clinically sensitive categories.
The comparison in one table
| Brand-name (reference) | Generic | |
|---|---|---|
| Active substance | Defined by the originator | Must be identical in kind and strength |
| Dosage form and route | Defined by the originator | Must be the same |
| Clinical trials | Full development programme: phases I–III | Not repeated; bioequivalence to the reference must be shown instead |
| Manufacturing standard | GMP, inspected | GMP, inspected — the same requirement |
| Excipients, colour, shape | Originator's formulation | May legally differ |
| Name | Trademarked brand | Usually the international non-proprietary name (INN) plus the maker |
| Price | Reflects recouped development and marketing | Typically far lower; falls further with competition |
Why the price gap is so wide
A generic manufacturer skips the largest cost in pharmaceutical development: the original clinical programme that established the molecule works. It must still fund manufacturing, quality systems, bioequivalence studies and registration — real costs, but an order of magnitude smaller.
Competition then drives the rest. When one generic enters the market the discount is modest; with several competitors the price of the molecule can fall by the large majority of its original level. This is a well-documented market effect, not evidence of a corner being cut.
The cases where switching deserves a conversation
For most medicines, substitution is routine and pharmacists do it every day. A few situations genuinely warrant discussing with your prescriber before switching — either between brand and generic, or between two different generics:
- Narrow therapeutic index drugs — warfarin, levothyroxine, ciclosporin, lithium, some antiepileptics. Small changes in blood levels can matter, so many clinicians prefer to keep a patient on one consistent product.
- Modified-release formulations — the release mechanism, not just the molecule, drives the effect, and different products can behave differently.
- Inhalers and injector devices — the device and technique differ, so a switch may require retraining even when the drug is identical.
- Known excipient intolerance — a different filler or dye can matter to a specific patient even though it is clinically inert for everyone else.
- Biologicals — these are not generics at all. Their follow-on versions are biosimilars, approved under a different and more demanding framework.
What the evidence shows on outcomes
Regulators in the U.S. and EU have both examined whether approved generics underperform in practice. The FDA's position, stated in its public guidance, is that generic drugs work in the same way and provide the same clinical benefit as their brand-name versions, and that a generic is required to be the same as the brand on the measures that determine clinical effect.
Where patients report a difference after a switch, the usual candidates are a change in tablet appearance affecting adherence, the nocebo effect, an excipient sensitivity, or a genuine formulation issue in a narrow-index drug. All four are worth reporting to your pharmacist, who can report a suspected quality defect onward to the regulator.
Frequently asked questions
Can my pharmacist substitute a generic without asking me?
This depends entirely on national law. In some countries substitution is the default unless the prescriber writes otherwise; in others the patient must consent. Ask your pharmacist what applies where you live.
Are 'branded generics' something different?
A branded generic is a generic sold under its own trademark rather than the molecule name. Regulatory status is identical to any other generic; only the marketing differs.